Anti-CGRP monoclonal antibodies: focus on safety


DOI: https://dx.doi.org/10.18565/pharmateca.2019.9.59-63

Ya.I. Ashikhmin (1), Yu.E. Azimova (1, 2)

1) University Headache Clinic, Moscow, Russia; 2) Research Institute of General Pathology and Pathophysiology, Moscow, Russia

Migraine is a common socially significant disease, which until recently had no specific preventive therapy. The advent of monoclonal antibodies to the calcitonin-gene related peptide (CGRP) system has introduced a new era in the treatment of migraine. Since CGRP is a powerful vasodilator, cardiac safety of drugs that block this peptide has been studied especially carefully. There was no evidence of a negative effect of CGRP blockers on hemodynamic parameters and the severity of ischemia in arterial occlusion. In the study with the monitoring of 1287 patients with cardiovascular diseases or their risk factors (diabetes mellitus, arterial hypertension, obesity, etc.), no negative effects of fremanizumab on the cardiovascular system, including blood pressure and electrocardiography parameters, were detected. According to a stress test, it was shown that intravenous administration of erenumab at a dose of 140 mg does not affect the exercise tolerance and the development of myocardial ischemia. Anti-CGRP monoclonal antibodies have high efficacy and safety.


For citations: Ashikhmin Ya.I., Azimova Yu.E. Anti-CGRP monoclonal antibodies: focus on safety. Farmateka. 2019;26(9):59–63. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.9.59-63 


About the Autors


Corresponding author: Yaroslav I. Ashikhmin, PhD, Cardiologist, Advisor to the Director General of the International Medical Cluster Foundation, University Headache Clinic, Moscow; Russia; e-mail: ya.ashikhmin@gmail.com
Address: 2, Build. 1, Molodogvardeiskaya Street, Moscow 121467, Russian Federation


Similar Articles


Бионика Медиа